Close Menu

Luminex

The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.

With the acquisition, Luminex has expanded its offering of flow-based detection systems and broadened direct interactions with researchers conducting cellular analysis.

Total revenues were down due to lower assay revenues, which shrank 11 percent from a year ago. Sample-to-answer molecular product revenues grew 15 percent.

Luminex has licensed the XCR Diagnostics Xtreme Chain Reaction nucleic acid amplification technology for an undisclosed amount.

The deal is expected to close by the end of 2018 and to contribute between $40 million and $50 million in revenues to Luminex in 2019.  

Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.

CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.

Clinicians identifying and treating S. aureus bloodstream infections reduced the median length of stay by 5.6 days and hospital cost by $13,341 per patient after using Luminex's assay.

The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.

A brief recap of Genetics/Genomics news the week of Jun 15, 2018: Epistem, Exosome Diagnostics, Luminex, Bluebee, Abomics, and OpGen

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.